Form 4: NeuroPace CMO's Tax Withholding on RSU Vesting

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, had 3,412 shares withheld to cover tax obligations upon the vesting of a restricted stock unit award on February 20, 2026.

Summary

• Martha Morrell, Chief Medical Officer of NeuroPace Inc. (NPCE), reported a transaction on February 20, 2026.
• The transaction involved the disposition of 3,412 shares of Common Stock.
• These shares were withheld by NeuroPace Inc. to satisfy tax withholding obligations related to the vesting of a restricted stock unit (RSU) award.
• The deemed price for the disposed shares was $14.34 per share.
• Following this transaction, Martha Morrell beneficially owns 75,322 shares of NeuroPace Inc. Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine, non-discretionary transaction for tax purposes related to equity compensation and does not indicate any change in company fundamentals or management sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding NeuroPace Inc.'s future performance or strategic direction.

Industry Context

StockSavvy.ai notes that tax-related share withholdings upon RSU vesting are a routine and non-discretionary event for executives receiving equity compensation, common across the medical device and biotechnology sectors. This transaction does not reflect a discretionary sale or a change in management's outlook on the company.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine tax-related transaction for executive compensation and does not reflect a change in company strategy or performance.

Key Dates

Keywords

NeuroPace, NPCE, Form 4, Insider Transaction, RSU Vesting, Tax Withholding, Martha Morrell, Chief Medical Officer